Actinium Pharmaceuticals, Inc. Class Action Reminder by Levi & Korsinsky

Investors who have invested in Actinium Pharmaceuticals, Inc. are being reminded of the pending class action lawsuit by Levi & Korsinsky. The lead plaintiff deadline for this class action lawsuit is on May 27, 2025. Actinium Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing targeted therapies for different types of cancers. The class action lawsuit against the company is related to allegations of violations of federal securities laws.

Shareholders who have incurred losses exceeding the threshold amount in Actinium Pharmaceuticals, Inc. are encouraged to participate in the class action lawsuit in order to potentially recover their losses. The lawsuit alleges that Actinium Pharmaceuticals, Inc. made false and misleading statements regarding the efficacy and market potential of its drug candidate, Iomab-B. The lawsuit claims that the company failed to disclose crucial information that later caused its stock price to plummet significantly.

According to the lawsuit, Actinium Pharmaceuticals, Inc. misled investors about the success of Iomab-B in clinical trials and its potential for FDA approval. It is alleged that the company overstated the drug candidate’s prospects in the market, leading to inflated stock prices. When the truth about Iomab-B’s actual efficacy and market potential emerged, investors suffered substantial financial losses as the stock price tumbled.

Investors who purchased Actinium Pharmaceuticals, Inc. stock between the specified dates and suffered losses are eligible to join the class action lawsuit. By participating in the lawsuit, investors have the opportunity to potentially recover their losses resulting from the alleged securities law violations by Actinium Pharmaceuticals, Inc.

The lead plaintiff in the class action lawsuit is pivotal, as they will act on behalf of other class members in pursuing the case against Actinium Pharmaceuticals, Inc. and seeking to recover losses incurred by shareholders. Investors who wish to be considered as the lead plaintiff in the class action lawsuit must file an application by the specified deadline.

Levi & Korsinsky is a national firm that specializes in securities litigation and has extensive experience in representing investors in class action lawsuits. The firm is committed to seeking justice for shareholders who have suffered losses due to securities law violations by companies such as Actinium Pharmaceuticals, Inc.

Investors who have been affected by the alleged misconduct of Actinium Pharmaceuticals, Inc. are urged to take action and participate in the class action lawsuit before the May 27, 2025 deadline. By joining the lawsuit, investors have the chance to hold the company accountable for its actions and potentially recover financial losses resulting from the misleading statements made by Actinium Pharmaceuticals, Inc. regarding its drug candidate, Iomab-B.